Biogennix LLC – FDA EIR, Apr 18, 2012

An FDA inspection of Biogennix LLC, a specification developer of Class II orthopedic bone void fillers, was conducted on April 17-18, 2012. This represented the firm's initial FDA inspection, performed under the regulatory framework for Medical Device Manufacturers. While no formal FDA-483 Inspectional Observations were issued, several critical observations were discussed with management.

Key issues identified included a failure to conduct management reviews according to the timeframe specified in the firm's previous procedure. Additionally, there was a lack of documented design review prior to releasing the Biogennix RPC granular product into full production. The inspection also highlighted that the risk analysis using FMEA did not consistently calculate risk scores both before and after mitigation steps. Finally, the company's complaint form lacked fields to capture specific patient demographic information essential for potential FDA MEDWATCH reporting.

Management acknowledged these observations and outlined corrective actions. These included revising procedures for management reviews, implementing a new design control procedure to ensure proper documentation of design reviews, developing a revised risk assessment procedure, and planning to update the complaint form to capture necessary patient data. The firm's registration was noted as current, and no other objectionable conditions, refusals, or samples were collected during the inspection.